All lobbying filings

TERUMO BCT, INC.

TERUMO BCT, INC. filed a Q1 report for TERUMO BCT, INC. on April 20, 2026.

Lobbying for TERUMO BCT, INC. · Medical technology company

All filings by TERUMO BCT, INC. · Everything TERUMO BCT, INC. has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$20,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Colorado

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Trade (domestic/foreign)

Global trade and tariffs

Health Issues

S.735/H.R. 1796 - Reauthorization of Sickle Cell Disease and Other Heritable Blood Disorders Research, Blood and cell collection, storage, and processing Blood donation supply and quality

Bills named in this filing 2

S. 735
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
H.R. 1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.